Trastuzumab in HER2-positive Biliary Tract Cancer
NCT03613168
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
4
Enrollment
OTHER
Sponsor class
Conditions
Cholangiocarcinoma
Biliary Tract Cancer
HER-2 Protein Overexpression
HER-2 Gene Amplification
Interventions
DRUG:
Trastuzumab
Sponsor
Changhoon Yoo